An interventional study of Hybrid coronary revascularization and Conventional revascularization in Coronary Artery Disease, sponsored by Rigshospitalet, Denmark. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark — 5 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Rigshospitalet, Denmark.
Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 14 with no phase, and was the 15th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark are open now, in 3 countries. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,048 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 331 across the 15 interventional studies, 105 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Coronary Artery Disease by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Coronary artery disease often necessitates complex interventions like coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) with stents. Hybrid coronary revascularization, a minimally invasive approach, integrates both methods for complete revascularization. This multicenter randomized trial involves 1200 patients, comparing hybrid coronary revascularization to CABG in a 1:1 ratio. Eligible participants have multi-vessel coronary disease and are referred for elective or sub-acute CABG. Inclusion criteria include age 18 or older, significant multi-vessel disease, and potential complete revascularization with both methods. Exclusion criteria include chronic kidney disease, pregnancy, contradiction to dual antiplatelet therapy, recent myocardial infarction, and acute revascularization. The hybrid group undergoes staged revascularization, combining minimally invasive grafting of the left interior mammary artery to the left anterior descending artery with PCI-stenting of remaining lesions. The control group undergoes conventional CABG with sternotomy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, or unplanned hospitalization, while secondary outcomes include periprocedural complications, cardiovascular mortality, hospital-free days within 90 days, angina frequency, and quality of life. Evaluation occurs 12 months after randomization. The trial commences in 2024, with inclusion expected to conclude in 5 years.
Background Cardiovascular diseases, mainly coronary artery disease (CAD), are the leading causes of death worldwide. CAD is characterised by the narrowing or blockage of blood flow in the coronary arteries often necessitating complex interventions like coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with drug-eluting stents. The preferred revascularisation strategy depends on several characteristics, one being the number of diseased vessels. Multi-vessel coronary artery disease (MVD) is defined as stenosis of at least two major coronary arteries.
Over the years, several large trials have concluded that CABG and PCI with newer-generation drug-eluting stents are both associated with improved survival rates compared to medical therapy.
CABG is still regarded as the gold standard for complex multi-vessel disease, with the cornerstone being the in-situ left internal mammary artery (LIMA) anastomosed to the left anterior descending artery (LAD).1 Current guidelines recommend CABG or PCI with equipoise in patients with one-vessel proximal LAD stenosis, two-vessel disease with proximal LAD stenosis, left main disease or three-vessel disease with lower complexity. The LIMA graft, with its excellent patency, has been shown to outperform PCI of the LAD and is in part responsible for the apparent success and survival benefit of CABG.3 However, saphenous vein grafts, the most common graft for non-LAD targets perform rather poorly, with graft failure ranging as high as 43%, 18 months after surgery. PCI with DES, especially with intravascular imaging, is documenting meagre failure rates and may consequently offer better results in non-LAD vessels than CABG with vein grafts does.
Despite its survival benefits, the CABG comes at the cost of a full sternotomy, necessitating longer rehabilitation. Patients may prefer less invasive treatment options if these are feasible and have consistent long-term results. The minimally invasive coronary artery bypass (MIDCAB) procedure was developed as a less invasive method for revascularisation. MIDCAB allows for the grafting of the anterior vessels through a small left anterior thoracotomy without the use of extracorporeal circulation. Thus, ensuring vital revascularisation with a lesser trauma.
Complete revascularisation has been established as the most important factor for survival. Recent data have showed comparable 10-year mortality in patients achieving this goal with either PCI or CABG.
Hybrid coronary revascularisation was developed to combine the best parts of the two revascularisation techniques, consisting of a minimally invasive grafting of the LIMA to LAD, and PCI of all functionally significant non-LAD stenoses. Theoretically, patients may obtain the survival benefit from the LIMA-LAD graft, from a less invasive approach and avoidance of vein graft failures.
However, to this date, hybrid coronary revascularisation is supported by very limited data. Only three small, randomised feasibility trials have been conducted, which all stated that the procedure is feasible but that larger randomised trials are necessary to determine if it is a suitable alternative to treating multi-vessel disease.
Trial objective The trial objective is to assess the beneficial and harmful effects of hybrid coronary revascularisation versus CABG in patients with multi-vessel coronary artery disease.
Trial design The trial investigators will conduct a multicentre randomised superiority trial comparing hybrid coronary revascularisation versus conventional CABG surgery in patients with multi-vessel coronary artery disease.
Patients will be randomised 1:1 to hybrid coronary revascularisation or CABG. The randomisation will be stratified according to clinical site and diabetes (yes/no).
Selection of participants All patients with multi-vessel coronary disease referred for a CABG will be discussed during the Heart Team Conference and considered for participation in the trial.
Inclusion criteria
Exclusion criteria
Trial intervention
Experimental intervention:
Coronary revascularisation will be conducted as a staged intervention. First, the MIDCAB will be conducted through a small left anterior thoracotomy, with endoscopic LIMA harvest and off-pump LIMA to LAD-grafting. Second, PCI with implantation of contemporary DES of all non-LAD lesions will be conducted within 4 weeks of the surgical procedure. Patients will receive dual antiplatelet therapy (DAPT) according to local routine and international guidelines.
A "reverse hybrid" with PCI preceding MIDCAB is also an option in patients with sub-acute coronary syndrome or CTO. Surgery will be conducted 3 months after PCI when it is safe to pause DAPT. PCI of CTO, guided by viability tests, may further be staged at up to 30 days after MIDCAB surgery.
Control intervention:
Coronary revascularisation will be conducted as a conventional CABG, through a sternotomy, on- or off-pump with grafting of all target vessels, according to local best practice. All graft types are permitted and, therefore, surgeons decide their own specific graft strategy.
CABG, MIDCAB, and PCI are all standard procedures performed routinely at the hospitals. Therefore, there is no expected increased risk for trial participants no matter which group they are randomized to.
The statistical analysis will adhere to the intention-to-treat principle, meaning that participants will be analyzed based on their originally assigned groups even if they undergo a crossover to other interventions.
Outcome measures
Primary outcome:
Secondary outcomes:
Exploratory outcomes:
Sample size and power estimation Provided that the incidence of all-cause mortality, a diagnosis of myocardial infarction, a diagnosis of stroke, or hospitalization in the control group is equal to 55%, an absolute risk reduction of 10% (corresponding to a relative risk reduction of 18.2%), α=0.05, beta=0.10 (giving a power of 90%) we will need 524 participants in the intervention and in the control group. Notably, a 10% absolute risk reduction corresponds to an incidence of either all-cause mortality, a diagnosis of myocardial infarction, a diagnosis of stroke, or hospitalization equal to 45% in the experimental intervention group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Complete revascularisation through a combined MIDCAB (LIMA-LAD graft trough a minimal invasive left anterior thoracotomy) and PCI (of all non-LAD stenoses)
Procedure: Hybrid coronary revascularization
Conventional CABG through a sternotomy
Procedure: Conventional revascularization
Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
Conventional revascularization with CABG of all significant stenoses through a sternotomy
A composite outcome of either all-cause mortality, a diagnosis of spontaneous myocardial infarction, a diagnosis of stroke, or any unplanned hospitalization
A composite outcome of either all-cause mortality, a diagnosis of spontaneous myocardial infarction, a diagnosis of stroke, or any unplanned hospitalization
Time frame: 12 months after randomization
Angina symptoms
Angina symptoms measured using Seattle Angina Questionnaire
Time frame: 12 months after randomization
Health related quality of life
Health related quality of life using EQ-5D
Time frame: 12 months after randomization
Hospital free days
Hospital free days
Time frame: 90 days after randomization
Procedural complications
Procedural complications defined as periprocedural myocardial infarction, unplanned re-intervention, stroke, BARC 3-5 bleeding complications or sternal wound infection
Time frame: 12 months after randomization
Plan to share: Yes — We plan to make all data publicly available in peer-review papers, after the trial has been finalized.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: At the end of the trial
Access criteria: In peer-review papers
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jan 2030, 42 months later.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 42 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.